Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06234605 · ClinicalTrials.gov registry record · Phase 1

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

A Phase 1 study of Renal Cell Carcinoma, sponsored by HiberCell.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
20
Study locations

NCT06234605 is a Phase 1 study of Renal Cell Carcinoma that is actively recruiting participants, run by HiberCell. The registered enrollment target is 80 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06234605, a Phase 1 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by HiberCell.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Belzutifan
  • DRUG HC-7366

Study Locations (20)

Texas

  • Texas Oncology - Dallas
  • University of Texas Southwestern Medical Center - Dallas
  • University Medical Center & Texas Tech Health Science Center - Lubbock

California

  • University of California San Diego Moores Cancer Center - La Jolla
  • Cedars-Sinai Medical Center - Los Angeles

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora
  • Rocky Mountain Cancer Centers, LLP - Lone Tree

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland
  • Cleveland Clinic - Cleveland

Washington

  • Swedish Medical Center - Seattle
  • Fred Hutchinson Cancer Center - Seattle

Arizona

  • University of Arizona Cancer Center - Tucson

Connecticut

  • Yale - New Haven Hospital - New Haven

Minnesota

  • HealthPartners Cancer Research Center - Saint Paul

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-04-29
Est. Completion 2027-11
Phase Phase 1

Sponsor

HiberCell

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06234605

The ClinicalTrials.gov registry entry for NCT06234605 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (67% lower). The listed sponsor is HiberCell, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Belzutifan is the first listed.

NCT06234605 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06234605 about?

NCT06234605 is a clinical study titled "A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma". This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patien...

What is the current status of trial NCT06234605?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-04-29. Estimated completion is 2027-11.

What conditions does trial NCT06234605 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT06234605?

The interventions under investigation include: Belzutifan (DRUG), HC-7366 (DRUG).

Who is sponsoring clinical trial NCT06234605?

This trial is sponsored by HiberCell, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06234605 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.